Barrington Research Maintains Outperform on LeMaitre Vascular, Maintains $92 Price Target
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has reiterated an 'Outperform' rating for LeMaitre Vascular (NASDAQ:LMAT) and maintained a price target of $92.
September 20, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barrington Research has reiterated its 'Outperform' rating for LeMaitre Vascular, maintaining a price target of $92. This suggests confidence in the company's future performance.
The reaffirmation of an 'Outperform' rating and a maintained price target of $92 by Barrington Research indicates a positive outlook for LeMaitre Vascular. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100